A case report of erythroderma in a patient with borderline leprosy on reversal reaction: a result of the exacerbated reaction?

Denis Miyashiro1**, Ana Paula Vieira2†, Maria Angela Bianconcini Trindade1, João Avancini1, José Antonio Sanches1 and Gil Benard2

Abstract

Background: Erythroderma is characterized by erythema and scaling affecting more than 90% of the body surface area. Inflammatory, neoplastic and, more rarely, infectious diseases may culminate with erythroderma. Diagnosis of the underlying disorder is therefore crucial to institute the appropriate therapy. Leprosy is a chronic infectious disease that is endemic in Brazil. Here we present an unusual case of leprosy and reversal reaction causing erythroderma, and we discuss the underlying immunological mechanisms which could contribute to the generalized skin inflammation.

Case presentation: We report a case of a patient with reversal reaction (RR) in borderline leprosy presenting with erythroderma and neural disabilities. Histopathology of the skin showed regular acanthosis and spongiosis in the epidermis and, in the dermis, compact epithelioid granulomas as well as grouped and isolated bacilli. This duality probably reflects the transition from an anergic/multibacillary state to a state of more effective immunity and bacillary control, typical of RR. Leprosy was successfully treated with WHO’s multidrug therapy, plus prednisone for controlling the RR; the erythroderma resolved in parallel with this treatment. Immunologic studies showed in situ predominance of IFNγ+ over IL-4+ lymphocytes and of IL-17+ over Foxp3+ lymphocytes, suggesting an exacerbated Th-1/Th-17 immunoreactivity and poor Th-2 and regulatory T-cell responses. Circulating Tregs were also diminished. We hypothesize that the flare-up of anti-mycobacteria immunoreactivity that underlies RR may have triggered the intense inflammatory skin lesions that culminated with erythroderma.

Conclusions: This case report highlights the importance of thorough clinical examination of erythrodermic patients in search for its etiology and suggests that an intense and probably uncontrolled leprosy RR can culminate in the development of erythroderma.

Keywords: Erythroderma, Leprosy, Reversal reaction, Regulatory T-cells

* Correspondence: denismiyashiro@gmail.com
† Equal contributors
1Department of Dermatology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Erythroderma is the maximal stage of skin inflammation, with erythema and scaling affecting more than 90% of the body surface area, and is considered a dermatologic emergency. Several diseases may culminate with erythroderma: exacerbation of preexisting dermatoses (psoriasis, atopic dermatitis, eczema), drug reactions, and cutaneous lymphomas. Erythroderma is rarely caused by infections (scabies, dermatophytosis) [1]. With the possible exception of two cases of leprosy patients presenting the erythroderma-related “deck-chair” sign, it has not been associated with leprosy [2, 3].

Leprosy is still endemic in several countries, including Brazil. It can cause severe skin alterations, neural disability, and, consequently, social and functional stigmas. Skin lesions are polymorphic, ranging from a single hypochromic hypoesthetic macule to diffuse skin infiltration [4]. This polymorphism may delay diagnosis, leading to progression of disabilities and increased risk of transmission.

Here we present an unusual case of leprosy and reversal reaction causing erythroderma, and we discuss the underlying immunological mechanisms which could contribute to the generalized skin inflammation.

Case presentation

A 63-year-old man presented with a two-month history of erythroderma, with diffuse infiltration of the skin. Axillary and inguinal areas were spared (Fig. 1a, b). Neurological examination disclosed amyotrophy of interosseous muscles of the hands, ulnar claw, paresthesia of hands and feet, and thickening of ulnar and fibular nerves (Fig. 1c). There was pronounced oedema of hands and feet (Fig. 1d). He had no history of skin diseases or exposure to new medications or allergens. The main initial hypothesis was cutaneous lymphoma due to the diffuse infiltration of the skin; however, the neurologic signs and symptoms raised the suspicion of leprosy.

Skin biopsies revealed epidermis with regular acanthosis, spongiosis and dermis with chronic epithelioid granulomatous infiltration in perivascular, periadnexial and perineural patterns (Fig. 2a, b). Fite-Faraco staining showed isolated and grouped acid-fast bacilli (Fig. 2c). Immunohistochemistry with anti-BCG was positive within nerves and inflammatory cells (Fig. 2d). Diagnosis of reversal reaction (RR) in borderline leprosy was made and the erythroderma was linked to the reaction. The patient was born in the countryside of Minas Gerais state, a highly endemic area for leprosy, but had been living in São Paulo city, that has low endemicity, for the last 23 years. There was no family history of leprosy. The patient was HIV negative.

Multidrug therapy with dapsone, clofazimine, and rifampicin (MDT) based on WHO recommendation was initiated. RR-associated neuritis was treated with prednisone 40 mg/day, amitriptyline 25 mg/day and gabapentin 300 mg/day. After 4 months, the prednisone dose was tapered to 10 mg/day, which was maintained until
completion of the MDT. Skin lesions had improved significantly after 6 months of treatment, and full resolution of erythrodema and neuritis was achieved when he completed the 12 months of MDT. No recurrence of erythrodema or RR occurred up to the last visit. The ulnar claw required surgical decompression; orthopedic shoes and physiotherapy sessions were used as adjuvant therapies, improving the neural sequelae.

Immunohistochemistry and peripheral blood cells cytometry were performed as previously described (Additional file 1) [5, 6]. During RR and erythrodema, IFN$\gamma$+ lymphocytes and IL-17+ lymphocytes (191 and 213 cells/mm$^2$, respectively) outnumbered IL-4+ lymphocytes and FoxP3+ lymphocytes (25 and 121 cells/mm$^2$, respectively) in the skin tissue (Fig. 3). Our previous study of leprosy patients with severe RR (without erythrodema, RR group, $n$ = 14) showed the opposite: FoxP3+ lymphocytes prevailed over IL-17+ lymphocytes (170 ± 23 vs. 114 ± 27 cells/mm$^2$) [6]. Patient’s circulating Tregs were also reduced as compared with the RR group (2.17% vs. 3.4 ± 0.4%). However, the patient’s Tregs expanded normally upon in vitro stimulation with mitogen (phytohemagglutinin) or $M$. leprae antigens (data not shown).

The CARE guidelines were followed in this article.

**Discussion and conclusions**

The immunological mechanisms underlying erythrodema and RR are not well established. RR would represent
episodes of exacerbated Th-1 responses triggered by release of antigens from bacilli killed either by mycobactericidal drugs or by spontaneous flare-ups of the antimycobacteria immunoreactivity in patients with borderline (unstable) immunity [7, 8]. In erythroderma, also a state of immune dysregulation, this issue is complicated by the fact that these conditions are caused by many different diseases.

This case-report brings some unusual immunological findings that probably reflect the interplay between leprosy and erythroderma. Histopathology analysis revealed compact epithelioid granulomas, suggesting an efficient immune response, but also presence of isolated and grouped bacilli (viable and degenerated) within nerves, suggesting a yet active mycobacterial infection. This duality probably reflects the patient’s transition from an anergic/multibacillary state to a state of more effective immune response and bacillary control.

However, the simultaneous development of erythroderma indicates that this transition evolved through a dysregulated immune response. This is supported by the marked in situ over-expression of IFN-γ compared with IL-4 (IL-4/IFN-γ=0.13), consistent with the in situ pattern seen in RR in borderline leprosy, but not in erythroderma patients [9]. It has been reported that benign forms of erythroderma (eg, idiopathic or caused by atopic dermatitis) present slight predominance of IFN-γ over IL-4 expression (IL-4/IFN-γ=0.6 and 0.9, respectively), while in malignant forms (eg, Sézary syndrome) IL-4 predominated (IL-4/IFN-γ=1.8) [10]. However more recently, other authors, using Th-1 and Th-2-specific transcription factors, showed that in erythrodermic psoriasis and atopic dermatitis Th-2 responses predominated largely over Th-1 responses [11]. Although the data on erythroderma are still scarce and controversial, they markedly differ from those seen in our patient. These differences probably reflect the immune response pattern of the underlying disease.

Tregs and Th-17 responses appear to be reciprocally regulated in leprosy [6, 12, 13]. Another unexpected finding in this patient was the in situ over-expression of IL-17+ T-cells compared with Tregs, which contrasts with our previous findings showing that in borderline leprosy patients development of RR is associated with the concomitant decrease in the frequency of IL-17+ T-cells and the increase in the frequency of Tregs in the lesions [6]. In addition, the patient’s number of circulating Tregs was decreased when compared with our previous data on the RR group [6]. These alterations seem to be a direct effect of the patient’s immunological environment because the capacity of the patient’s Tregs to expand in vitro was preserved.

The balance among distinct T-cell subtypes that participate in a host’s cell-mediated immune response is tightly regulated through well-defined counter-regulatory mechanisms such as those that exist between Th-1 and Th-2 and between Th-17 and Tregs [14, 15]. We thus propose that the mechanisms underlying cutaneous immunological phenomena that culminate with erythroderma in our patient would be triggered by the flare-up of antimycobacteria Th-1 immune response. This blocked the local Th-2 immunity, favoring full expression of Th-17 responses while inhibiting the Treg pathway. Inhibition of the latter would, in turn, leave unchecked the cutaneous Th-1/Th-7 inflammation and subsequent development of erythroderma. We also hypothesize that MDT, concomitant with prednisone used for controlling the RR, contributed to the clinical improvement of erythroderma by reducing the mycobacteria burden. Further studies of case series of such patients are needed to confirm our hypothesis, since it was based on a single observation.

In conclusion, this case report highlights the importance of a thorough clinical examination of erythodermic patients in search for its etiology and suggests that an intense and probably uncontrolled leprosy RR can culminate in the development of erythroderma.

### Additional file

- **Additional file 1:** Immunohistochemistry staining for Foxp3, IL-4, IL-17 and IFN-γ of the biopsies of skin lesions. Material and methods for the immunohistochemistry stainings. (DOCX 16 kb)

### Abbreviations

- MDT: Multidrug therapy; RR: Reversal reaction; Th: T-helper

### Acknowledgements

We thank Dr. Marcelle Almeida de Sousa Nogueira and Dr. Luisa Juliato Molina Tinoco for assistance in reviewing the medical records; Dr. Neusa Yuriko Sakai Valente and Dr. Marcelo Abrantes Giannotti for pathology review; and Dr. Anna S. Shafferman Levin for English revision.

### Funding

Reagents for the immunological study of the patient were provided through Fundação de Amparo à Pesquisa do Estado de São Paulo # 2014/15286–0.

### Availability of data and materials

All data generated or analyzed during this study are included in this published article.

### Authors’ contributions

DM, MABT, JA, and JAS performed clinical and pathological assessment. APV and GB performed immunological studies. DM and APV drafted the manuscript, MABT, JAS, and GB edited the manuscript; DM finalized the case report and prepared it for publication. All authors read and approved the final manuscript.

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

### Competing interests

The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Dermatology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil. 2Clinical and Experimental Allergy and Immunology Laboratory LIM-56, University of São Paulo Medical School, São Paulo, Brazil.

Received: 4 September 2017 Accepted: 14 December 2017

References
1. Sehgal VN, Srivastava G, Sardana K. Erythroderma/exfoliative dermatitis: a synopsis. Int J Dermatol. 2004;43(1):39–47.
2. Shenoy WM, Bendigera MA, Kamath PR, Vishal B. Diffuse leprosy with “deck-chair” sign. Indian Dermatol Online J. 2015;6(3):204–6.
3. Prothar A, Narang T, Salia UN, Dogra S. Deck chair sign in lepromatous leprosy. Lepr Rev. 2013;84(3):252–4.
4. White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev. 2015;28(1):80–94.
5. Palermo ML, Pagliari C, Trindade MA, Yamashita Fuji TM, Duarte AJ, Cacere CR, et al. Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy. Am J Trop Med Hyg. 2012;86(5):878–83.
6. Vieira AP, Trindade MA, Pagliari C, Avancini J, Sakai-Valente NY, Duarte AJ, et al. Development of type 2, but not type 1, leprosy reactions is associated with a severe reduction of circulating and in situ regulatory T-cells. Am J Trop Med Hyg. 2016;94(4):721–7.
7. Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management. Lepr Rev. 2008;79(4):372–86.
8. Fonseca AB, Simon MD, Cazzaniga RA, de Moura TR, de Almeida RP, Duthie MS, et al. The influence of innate and adaptive immune responses on the differential clinical outcomes of leprosy. Infect Dis Poverty. 2017;6(1):5.
9. Verhagen CE, Wierenga EA, Buffing AA, Chand MA, Faber WR, Das PK. Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like mycobacterium leprae T cell reactivity in lesional skin: a follow-up study. J Immunol. 1997;159(9):4474–83.
10. Sigurdsson V, Toonstra J, Bihari IC, Bruijnzeel-Koomen CA, van Vloten WA, Thepen T. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study. J Cutan Pathol. 2000;27(9):429–35.
11. Moy AP, Murali M, Krosinski D, Duncan LM, Nazarian RM. Immunologic overlap of helper T-cell subtypes 17 and 22 in Erythrodermic psoriasis and atopic dermatitis. JAMA Dermatol. 2015;151(7):753–60.
12. Sadhu S, Khaitan BK, Joshi B, Sengupta U, Nautiyal AK, Mitra DK. Reciprocity between regulatory T cells and Th17 cells: relevance to polarized immunity in leprosy. PLoS Negl Trop Dis. 2016;10(1):e0004338.
13. Saini C, Siddiqui A, Ramesh V, Nath I. Leprosy reactions show increased Th17 cell activity and reduced FOXP3+ Tregs with concomitant decrease in TGF-beta and Increase in IL-6. PLoS Negl Trop Dis. 2016;10(4):e0004592.
14. Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol. 2000;85(1):9–18. quiz, 21
15. Noack M, Mossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13(6):668–77.